Jump to content

Study promotes chemo plus radiation at treatment start


Recommended Posts

Chemotherapy, radiation combinations may boost survivalSource: (cancerfacts.com)

Friday, September 02, 2005

PHILADELPHIA – Sept. 2, 2005 – A new study adds to growing evidence that giving patients both chemotherapy and radiation in the beginning of treatment may help patients live longer.

The research team led by Dr. Walter Curran, professor and chair of radiation oncology at Jefferson Medical College, and Jefferson's Kimmel Cancer Center found that a combination that delivered chemotherapy simultaneously with radiation followed by a second chemotherapy regimen added several months of survival compared to standard therapy.

"This is a further step in looking at what is the best combination of two chemotherapy agents with radiation, which will enable us to move forward and study it more systematically," Curran said in a news release. "There are new biologic agents we want to test with chemotherapy, with radiation and with both. Finding the best combination of chemotherapy and radiation provides a template by which we can test these agents."

While researchers have learned in the last decade that combining chemotherapy with radiation is better than radiation alone for treating non-small cell lung cancer patients with locally advanced cancer that is confined to the lungs, finding the right combination of drugs and the best timing of treatment has been problematic.

In the multicenter, clinical trial, the researchers compared three different approaches to treating inoperable non-small-cell lung cancer that had not spread beyond the lungs. They divided more than 250 patients into three treatment arms.

One group received chemotherapy before radiation. A second group had chemotherapy before and during radiation. Patients in the third arm received chemotherapy and radiation at the same time, then an additional cycle of chemotherapy. Each arm had the same schedule of radiation and were given the same two standard chemotherapy agents, carboplatin and paclitaxel. The results appear Sept. 1, 2005 in the Journal of Clinical Oncology.

Curran and his colleagues found that the patients in the third arm did best, living several months more on average when compared against the standard treatment.

"Researchers are already looking at targeted agents such as bevacizumab, cetuximab and other agents with chemotherapy and radiation in lung cancer," he says. "This kind of study will help guide us as to which schedule to use."

Other institutions that participated in the trial include medical centers at the University of Pittsburgh and Vanderbilt University and Rush University Medical Center.

Non-small-cell lung cancer accounts for about 80 percent of all cases of lung cancer. An estimated 40,000 Americans are diagnosed each year with locally advanced disease.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.